Today T2 Biosystems was removed from the Tailwinds Select Portfolio at a price of $7.22. This represents a 38% return in the slightly less than 2 months which we had it in the portfolio, so chalk it up as...
Tailwinds' Take: the news, which had been leaked but is now official, about FDA approval being a Q2 event will likely weigh on the shares for a couple weeks. Expect strength at month end, heading into approval. The bigger...
Tailwinds' Take: further confirmation of the effectiveness of T2's system. We are highly confident in near-term approval. Even better, many predict slow uptake; we disagree and studies like this demonstrate why we think TTOO will surprise on the upside...
Sepsis is a state of an infectious disease, starting when a bacteria or fungus enters a person’s bloodstream, that can lead to tissue damage, organ failure, and death. Sepsis is infamously called “The Silent Killer” due to its incognito...
We have added T2 Biosystems to the Select Portfolio. T2 is well positioned to receive FDA approval on their sepsis diagnostic sometime in Q1. This appears to be a disruptive diagnostic, that will take significant market share over time. We...
LEXINGTON, Mass., Jan. 04, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, today announced preliminary revenue and business results for the three months ended December 31, 2017 and provided an...
LEXINGTON, Mass., Nov. 20, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, today announced new data presented on the T2Sepsis Solution™ during the Association for Molecular Pathology (AMP) 2017 Conference...